Platinum versus immunotherapy for early resectable non-small cell lung cancer
A protocol for systematic review and meta analysis
Zhangwei Tong, MB, Fei Luo, MB, Xiaojie Yang, MB, Mingqiang Kang, MD, PhD, Jiangbo Lin, MD, PhD*

1. Introduction

Globally, lung cancer is the second most common malignancy. It is highly malignant and is the leading cause of cancer-related death.\(^1\) Non-small cell lung cancer (NSCLC) accounts for about 85% of the newly diagnosed lung cancer cases each year, which is the most common pathological type of lung cancer.\(^2,3\)

Surgical resection of early resectable NSCLC offers potential therapeutic opportunities for patients considered to be the best treatment.\(^4\) The 5-year survival rate of patients with pathological stage Ia to IIa NSCLC after surgery is 73% to 25%.\(^5,6\) However, there is no suitable treatment for the recurrence or metastasis of NSCLC. The 5-year survival rate of the patients can be increased by about 5% after the operation.\(^7-9\)

However, adjuvant radiotherapy is not recommended for postoperative adjuvant therapy of early-stage NSCLC because it can significantly increase the mortality rate of patients by about 7% in 2 years.\(^6,10,11\) With the emergence of molecular targeted therapy and immunotherapy, postoperative adjuvant therapy has become diversified.\(^12\) At present, although there is not enough evidence to support that PD1/PD-L1 inhibitors can effectively improve postoperative outcomes, more high-quality clinical trials are underway or have been published.
Objective to evaluate the efficacy of postoperative chemotherapy (platinum based chemotherapy and immunotherapy) in patients with or without radiotherapy for NSCLC, and obtain reliable evidence. We will conduct a systematic review and comprehensive analysis of published or unpublished relevant trials, and then compare these with the postoperative treatment methods of patients with NSCLC, so as to provide reference for clinicians and formulate the best treatment strategy.

2. Objective
We will evaluate the efficacy of postoperative adjuvant therapy (platinum based chemotherapy and immunotherapy) with or without radiotherapy for patients with NSCLC.

3. Methods
This protocol is conducted according to the preferred reporting items for systematic review and meta-analysis protocols statement.[13] We will report the results of this systematic review and meta-analysis adhere to the preferred reporting items for systematic reviews and meta-analysis guidelines.[14] This protocol has been registered in the INPLASY network (registration number: INPLASY202080064).

3.1. Patient and public involvement
This study will be based on published or unpublished studies and records and will not involve patients or the public directly.

3.2. Eligibility criteria
3.2.1. Types of studies. Randomized controlled trials and quasi-randomized controlled trials published or unpublished will be included, which have been completed and compared postoperative platinum-base chemotherapy versus immunotherapy for patients with NSCLC.

3.2.2. Types of participants. The participants will be adults diagnosed with resectable early NSCLC histologically or cytologically confirmed who were treated with platinum-based chemotherapy, or immunotherapy after surgery. No restrictions on ethnicity, sex, education, and economic status will be applied.

3.2.3. Types of interventions. According to the means of postoperative chemotherapy for patients with resectable early NSCLC, the trials included will be divided into the following categories.

- immunotherapy versus molecular targeted therapy
- immunotherapy versus anti-angiogenic agents
- postoperative platinum-base chemotherapy versus molecular targeted therapy
- platinum-based chemotherapy versus anti-angiogenic agents
- platinum-based chemotherapy versus immunotherapy

3.2.4. Types of outcome measures
3.2.4.1. Primary outcomes. The primary outcomes will be postoperative overall survival of patients with resectable early NSCLC who were treated with postoperative chemotherapy.

3.2.4.2. Secondary outcomes. We will assess the 5-year survival, median survival, recurrence-free survival, quality of life, and adverse events or complications of patients with resectable early NSCLC who were treated with postoperative chemotherapy.

3.3. Information sources
We will search Pubmed (Medline), Embase, Google Scholar, Cancerlit, and the Cochrane Central Register of Controlled Trials for related studies published before June 20, 2021 without language restrictions.

3.4. Search strategy
We will use the relevant keywords or subject terms adhered to Medical Subject Heading terms to search for eligible studies in the electronic databases which were mentioned above without language restrictions. The Pubmed search strategies are shown in Table 1.

**Table 1**

| Pubmed search strategies. |
|---------------------------|
| # 1 | Carcinoma, Non Small Cell Lung[Title/Abstract] OR Carcinomas, Non-Small-Cell Lung[Title/Abstract] OR Lung Carcinoma, Non-Small-Cell[Title/Abstract] OR Lung Carcinomas, Non-Small-Cell[Title/Abstract] OR Non-Small-Cell Lung Carcinomas[Title/Abstract] OR Nonsmall Cell Lung Cancer[Title/Abstract] OR Non-Small-Cell Lung Carcinoma[Title/Abstract] OR Non Small Cell Lung Carcinoma[Title/Abstract] OR Non-Small-Cell Lung Cancer[Title/Abstract] |
| # 2 | Stage I OR Stage II OR Stage III |
| # 3 | anti-angiogenic agents OR bevacizumab OR remolumab OR parrumab |
| # 4 | immunotherapy OR anti-PD-1 antibodies OR anti-PD-L1 antibodies OR nivolumab OR pembrolizumab OR durvalumab OR atezolizumab OR avelumab |
| # 5 | randomized controlled trial[Publication Type] OR controlled clinical trial[Publication Type] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab]OR trial[tiab] OR groups[tiab] NOT (animals[mh] NOT humans[mh]) |
| # 6 | # 1 AND # 2 AND # 3 AND # 4 AND # 5 |
3.5. Data collection and analysis
We will utilize the measures described in the Cochrane Handbook for Systematic Reviews of Interventions to pool the evidence.\(^{[15]}\)

3.5.1. Study selection. Two reviewers (ZWT, FL) will investigate each title and abstract of all literatures searched independently and identify whether the trials meet the inclusion criteria as designed and described in this protocol. Two authors (ZWT, FL) will in duplicate and independently screen the full text of all potential eligible studies to exclude irrelevant studies or determine eligibility. The 2 reviewers will list all the studies included and document the primary reasons of exclusion for studies that do not conform to the inclusion criteria. Disagreements between the 2 authors will be resolved by discussing with the third author (XJY), if necessary, consulting with the fourth author (JBL). We will show the selection process in details in the preferred reporting items for systematic reviews and meta-analysis flow chart.

3.5.2. Data extraction and management. The 2 authors (ZWT, FL) will extract the following data independently from the studies included.
- Study characteristics and methodology: publication date, the first author, country, randomization, study design, periods of data collection, follow-up duration, total duration of study, withdrawals, and so on.
- Participant characteristics: gender, age, tumor stage, pathology diagnosis, ethnicity, performance status, history of smoking, pathologic tumor size, inclusion criteria, and so on.
- Interventions: type of operation, extent of resection, therapeutic means, drugs, dosage, modality, frequency of administration, and so on.
- Outcome and other data: overall survival, 5-year survival, median survival, disease-free survival, 95% confidence intervals (CIs), recurrence time, quality of life, adverse events, complications, and so on.

We will record all the date extracted in a pre-designed table and consult the first author of the trial by e-mail before determining eligibility, if the reported data of which are unclear or missing.

3.6. Assessment of risk of bias in included studies
Two authors (ZWT, FL) will use the Cochrane Handbook for Systematic Reviews of Interventions to assess the risk of bias of each study included independently based on the following ranges: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete outcome data (attrition bias); selective outcome reporting (reporting bias); other bias.\(^{[13]}\) Each domain will be assessed as high, low or uncertain risk of bias. The results and details of assessment will be reported on the risk of bias graph.

3.7. Data analysis
The data will be synthesized by Review Manager 5.3 software. We will conduct a systematic review and meta-analysis only if the data gathered from included trials are judged to be similar enough to ensure a result that is meaningful. The Chi\(^2\) test and I\(^2\) statistic will be used to assess statistical heterogeneity among the trials included in matched pairs comparison for standard meta-analysis. The random effect model will be applied to analyze the data, if there is substantial heterogeneity (\(P < .1\) or I\(^2\) statistic > 50%) and the trials will be regarded to be obvious heterogeneous. Otherwise, we will utilize fixed effect model to analyze the data. Mantel–Haenszel method will be adopted to pool of the binary data. The results will be reported in the form of relative risk between 95% CI of the date. The continuous data will be pooled by inverse variance analysis method and the results will be shown in the form of standardized mean difference with 95% CI of the date.

3.7.1. Subgroup analysis. If there is high heterogeneity (I\(^2\) statistic > 50%) and the data are sufficient, subgroup analysis will be conducted to search potential causes of heterogeneity. Subgroup analysis will be performed in different methods of postoperative adjuvant therapy, ethnicity, history of smoking, tumor stage, and type of operation.

3.7.2. Sensitivity analysis. Sensitivity analysis will be conducted to assess the reliability and robustness of the aggregation results via eliminating trials with high bias risk.

3.8. Publication bias
If there are 10 or more than 10 trials included, we will construct a funnel plot and use Egger test to assess publication bias. If reporting bias is suspected, we will consult the study author to get more information. If publication bias does exist, we will apply the fill and trim method to analyze publication bias in the trials.\(^{[16]}\)

3.9. Evidence evaluation
We will evaluate all the evidence according to the criteria of grading of recommendations, assessment, development, and evaluation (imprecision, study limitations, publication bias, consistency of effect, and indirectness bias). The quality of all evidence will be evaluated as 4 levels (high, moderate, low, and very low).\(^{[17]}\)

4. Discussion
The 5-year survival rate of NSCLC with pathological stage IA to IIIA was 73% to 25%. There was no suitable treatment for recurrence and metastasis of NSCLC. Postoperative adjuvant therapy is a necessary means to improve the overall survival rate and quality of life of patients with early resectable NSCLC. With the emergence of molecular targeted therapy and immunotherapy, postoperative adjuvant therapy has become diversified. It is a challenge for clinical oncologists to integrate different therapies to treat early NSCLC. Therefore, it is necessary to explore the diversity of adjuvant therapy to determine the optimal treatment strategy for each resectable NSCLC patient. The purpose of this study is to provide a reliable basis for integrating different treatment methods and formulating the optimal treatment strategy for early NSCLC.

Author contributions
Conceptualization: Zhangwei Tong, Fei Luo, Mingqiang Kang.
Data curation: Zhangwei Tong, Fei Luo, Mingqiang Kang.
Formal analysis: Zhangwei Tong, Fei Luo, Xiaojie Yang, Mingqiang Kang.
Funding acquisition: Zhangwei Tong.
Investigation: Zhangwei Tong, Jiangbo Lin.
Methodology: Zhangwei Tong.
Project administration: Zhangwei Tong.
Resources: Mingqiang Kang.
Software: Mingqiang Kang.
Supervision: Jiangbo Lin.
Validation: Jiangbo Lin.
Visualization: Jiangbo Lin.
Writing – review & editing: Jiangbo Lin.

References
[1] Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:324.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018.
[4] Scott WJ, Howington J, Feigenberg S, et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:2348–425.
[5] Chevalier TL. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol 2010;21 Suppl 7:vii196–198.
[6] Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:1462–74.
[7] Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003;95:1453–61.
[8] Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or III Annon-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453–61.
[9] Fairlamb DJ, Spiro SG, Gower N, et al. O-212 the big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting. Lung Cancer 2002;41:S62.
[10] Gomez DR, Komaki R. Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies. Cancers 2012;4:307–22. Videtic GM, Chang JY, Chetty IJ, et al. ACR appropriateness criteria early-stage non-small-cell lung cancer. Am J Clin Oncol. 2014;37:201–207.
[11] Mcdonald F, De WM, Hendriks LE, et al. Management of stage I and II nonsmall cell lung cancer. Eur Respir J 2017;49:1600764.
[12] Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical Research Ed) 2016;354:i4086.
[13] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed) 2009;339:b2700.
[14] Shuster JJ. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 2011. Julian P.T. Higgins and Sally Green, Editors. Research Synthesis Methods 2011;2:126–30.
[15] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bri Med J 2011;343:d5928.
[16] Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods 2012;3:161–76.
[17] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed) 2011;343:d5928.